These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25720079)

  • 21. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis.
    Brekelmans MPA; Ginkel KV; Daams JG; Hutten BA; Middeldorp S; Coppens M
    J Thromb Thrombolysis; 2017 Jul; 44(1):118-129. PubMed ID: 28540468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists.
    de Koning MLY; Fischer K; de Laat B; Huisman A; Ninivaggi M; Schutgens REG
    J Thromb Haemost; 2017 May; 15(5):868-875. PubMed ID: 28296129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombin generation in real life bleeding patients on oral anticoagulants reversed (or not) with (activated) prothrombin complex concentrate.
    Teissandier D; Moustafa F; Denaives A; Lebecque B; Blondonnet R; Pereira B; Monfoulet LE; Sinegre T; Schmidt J; Lebreton A
    Thromb Res; 2023 Mar; 223():184-193. PubMed ID: 36764085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation.
    Riess HB; Meier-Hellmann A; Motsch J; Elias M; Kursten FW; Dempfle CE
    Thromb Res; 2007; 121(1):9-16. PubMed ID: 17407788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial.
    Steiner T; Poli S; Griebe M; Hüsing J; Hajda J; Freiberger A; Bendszus M; Bösel J; Christensen H; Dohmen C; Hennerici M; Kollmer J; Stetefeld H; Wartenberg KE; Weimar C; Hacke W; Veltkamp R
    Lancet Neurol; 2016 May; 15(6):566-73. PubMed ID: 27302126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weight-Based Dosing Versus a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate in Obese Patients Requiring Vitamin K Antagonist Reversal.
    Elsamadisi P; Cepeda MAG; Yankama T; Wong A; Tran Q; Eche IM
    Am J Cardiovasc Drugs; 2021 May; 21(3):355-361. PubMed ID: 33150496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy.
    Sobrino Jiménez C; Romero-Garrido JA; García-Martín Á; Quintana-Díaz M; Jiménez-Vicente C; González-Del Valle L; Herrero Ambrosio A; Benedí-González J
    Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e66-e71. PubMed ID: 32591479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin.
    Chapman SA; Irwin ED; Beal AL; Kulinski NM; Hutson KE; Thorson MA
    Ann Pharmacother; 2011 Jul; 45(7-8):869-75. PubMed ID: 21775690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal.
    Refaai MA; Goldstein JN; Lee ML; Durn BL; Milling TJ; Sarode R
    Transfusion; 2015 Nov; 55(11):2722-9. PubMed ID: 26135740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse Events Following International Normalized Ratio Reversal in Intracerebral Hemorrhage.
    Laible M; Jenetzky E; Beynon C; Müller OJ; Sander P; Schüler S; Purrucker J; Möhlenbruch M; Steiner T; Veltkamp R; Ringleb PA; Rizos T
    Cerebrovasc Dis; 2016; 42(5-6):446-454. PubMed ID: 27536779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal: Does One Dose Fit All?
    Schwebach AA; Waybright RA; Johnson TJ
    Pharmacotherapy; 2019 May; 39(5):599-608. PubMed ID: 30892733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Point-of-care reversal treatment in phenprocoumon-related intracerebral hemorrhage.
    Rizos T; Jenetzky E; Herweh C; Hug A; Hacke W; Steiner T; Veltkamp R
    Ann Neurol; 2010 Jun; 67(6):788-93. PubMed ID: 20517940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing the dose of three-factor prothrombin complex concentrate in traumatic brain injury patients on warfarin therapy.
    Huynh TK; Costello JL; Rebuck JA
    Pharmacotherapy; 2014 Mar; 34(3):260-4. PubMed ID: 24338807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban.
    Dinkelaar J; Molenaar PJ; Ninivaggi M; de Laat B; Brinkman HJ; Leyte A
    J Thromb Haemost; 2013 Jun; 11(6):1111-8. PubMed ID: 23578206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
    Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
    Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Four-factor prothrombin complex concentrate dose response relationship with INR for warfarin reversal.
    Yohe AS; Livings SE
    Am J Emerg Med; 2019 Aug; 37(8):1534-1538. PubMed ID: 31130370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prothrombin complex concentrate accelerates international normalized ratio reversal and diminishes the extension of intracranial hemorrhage in geriatric trauma patients.
    Edavettal M; Rogers A; Rogers F; Horst M; Leng W
    Am Surg; 2014 Apr; 80(4):372-6. PubMed ID: 24887668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists.
    Tripodi A; Primignani M; Braham S; Chantarangkul V; Clerici M; Moia M; Peyvandi F
    Dig Liver Dis; 2016 Oct; 48(10):1208-13. PubMed ID: 27470055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticoagulation Reversal Strategies for Left Ventricular Assist Device Patients Presenting with Acute Intracranial Hemorrhage.
    Wong JK; Chen PC; Falvey J; Melvin AL; Lidder AK; Lowenstein LM; Miranpuri AS; Knight PA; Massey HT
    ASAIO J; 2016; 62(5):552-7. PubMed ID: 27347708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate.
    Woo CH; Patel N; Conell C; Rao VA; Faigeles BS; Patel MC; Pombra J; Akins PT; Axelrod YK; Ge IY; Sheridan WF; Flint AC
    World Neurosurg; 2014 Jan; 81(1):110-5. PubMed ID: 23220122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.